Shire’s extended-release version of non-stimulant Intuniv has been approved in Europe as a treatment for children and adolescents with attention-deficit hyperactivity disorder.
Specifically, Intuniv (guanfacine hydrochloride extended release) is indicated for the treatment of ADHD in children and adolescents six to 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. The drug must be used as a part of a comprehensive ADHD treatment programme, “typically including psychological, educational and social measures,” Shire noted.
Perry Sternberg, head of neuroscience at Shire, said “the importance of simply providing physicians with the ability to choose the non-stimulant option that may best suit the needs of their patients should not be overlooked, considering the complexities and different manifestations of the disorder in children and adolescents”.
There have been concerns raised about youngsters abusing ADHD stimulants, crushing them up and snorting them.